LifeSci Capital initiated coverage of Kura Oncology (KURA) with an Outperform rating and $30 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on KURA: Kura Oncology downgraded to Hold from Buy at Stifel Kura Oncology announces Ziftomenib Phase 1 results in The Lancet Kura Oncology Welcomes New Director Michael Vasconcelles Kura Oncology appoints Vasconcelles to board of directors